Our research also establishes that a potential inflammatory biomarker for NASH could be high IL-23 plasma levels, while high levels of IL-17A and low levels of IL-10 could be used as plasma biomarkers of CHC. Here, IL17A is linked to metabolic dysfunction-associated steatohepatitis.